Table 3.
Univariate and multivariate Cox regression analyses for PFS of patients (n=218)
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age | ||||
| >59 years vs ≤59 years | 1.083 (0.768-1.528) | 0.648 | ||
| Gender | ||||
| Male vs Female | 0.740 (0.496-1.104) | 0.141 | ||
| Histologic type | ||||
| Non-clear cell vs clear cell type |
1.214 (0.753-1.956) | 0.426 | ||
| Tumor nucleus grade | ||||
| 3+4 vs 2 | 1.043 (0.740-1.471) | 0.810 | ||
| Initial TNM stage | ||||
| III+ IV vs I+ II | 1.219 (0.863-1.721) | 0.260 | ||
| Tumor size | ||||
| Per 1cm increase | 1.097 (0.917-1.313) | 0.311 | ||
| Pulmonary metastasis | ||||
| Present vs Absent | 1.691 (1.169-2.445) | 0.005 | 1.409 (0.954-2.082) | 0.085 |
| Systemic therapy | ||||
| Sorafenib vs Sunitinib | 0.811 (0.565-1.163) | 0.254 | ||
| Tumor necrosis | ||||
| Present vs Absent | 1.259 (0.873-1.815) | 0.217 | ||
| Metastatic organ number | ||||
| ≥2 vs 1 | 1.002 (0.695-1.445) | 0.991 | ||
| tPD-L1 | ||||
| Positive vs Negative | 1.220 (0.849-1.753) | 0.283 | 0.767 (0.483-1.219) | 0.262 |
| sPD-L1 | ||||
| Positive vs Negative | 1.750 (1.217-2.516) | 0.003 | 1.718 (1.107-2.666) | 0.016 |
| Treg | ||||
| High vs Low | 1.928 (1.397-2.046) | 0.042 | 1.568 (1.025-2.401) | 0.038 |
| CD8 | ||||
| High vs Low | 0.645 (0.457-0.910) | 0.013 | 0.574 (0.384-0.858) | 0.007 |
| CD4 | ||||
| High vs Low | 0.738 (0.523-1.039) | 0.082 | 0.724 (0.473-1.109) | 0.138 |
| PD-1 | ||||
| High vs Low | 1.605 (1.115-2.311) | 0.011 | 1.657 (1.106-2.483) | 0.014 |
| IMDC | 0.030 | 0.044 | ||
| Favorable | 1.000 | 1.000 | ||
| Intermediate | 0.975 (0.608-1.562) | 1.083 (0.663-1.769) | ||
| Poor | 1.748 (0.992-3.079) | 1.872 (1.018-3.440) | ||
| IS | 0.002 | |||
| Low | 1.000 | |||
| Intermediate | 1.364 (0.927-2.007) | |||
| High | 2.148 (1.318-3.501) | |||
Abbreviations: tPD-L1,tumor cells PD-L1 expressions; sPD-L1, stromal immune cells PD-L1 expressions; CI, confidence interval; IMDC, International Metastatic Renal Cancer Database Consortium; PFS, progression free survival; IS, Immunoscore.